ArticleBMC complementary medicine and therapies2026
Hepatotoxicity prediction for traditional Chinese medicine: a two-step in silico framework integrating network and machine learning approaches.
Article in BMC complementary medicine and therapies, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Traditional Chinese medicine (TCM) has gained increasing attention due to several severe cases of herb-induced liver injury over the last few decades. Due to the intricate components and complex internal interactions, the identification of hepatotoxic ingredients in TCM remains a significant challenge. In this study, we proposed a novel two-step in silico framework, which integrates a network-based systems pharmacology approach and a machine learning-based consensus model, to identify potential hepatotoxicity from TCM-derived compounds. Compared to currently available tools, our method showed superior predictive capability in terms of accuracy (0.76) and F1 score (0.72) on a natural product-specific benchmark test set. Based on the two-step in silico framework, we conducted a comprehensive screening of 3,882 TCM compounds, revealing that 133 exhibited potential high-risk hepatotoxicity, including 45 (33.8%) corroborated by clinical and experimental evidence. Cell viability tests and serum biochemistry analyses on HepG2 cells confirmed the significant hepatotoxicity of the predicted compounds, including dehydroevodiamine, monocrotaline, tetrahydrocoptisine, citric acid, and eugenol. We next performed pharmacovigilance assessment of hepatotoxicity for the top 100 commonly used TCM herbs in clinical practice, prioritized the high-risk herbs, and explored the hepatotoxic mechanisms of TCM. Finally, we selected Rheum palmatum L. (Dahuang) as case study to showcase how the proposed two-step in silico framework aids in accurately identifying the compositions and understanding the underlying molecular mechanisms of TCM-induced liver injury. Overall, this study demonstrates a potent computational toxicology framework for TCM-induced hepatotoxicity prediction, aiming to provide guidance for the clinical use of TCM.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.